EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review

Mervat Mattar, Ali Bazarbachi, Omar Abduljalil, Bassam Francis, Arif Alam, Vivian Blunk

Clinical Hematology International · 22.02.2024 · 6 (1)

DOI: 10.46989/001c.92555 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Hematology International, online erschienen am 22.02.2024. Verfasst von Mervat Mattar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Internal Medicine Hematology Unit, Cairo University, Cairo, Egypt. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Globally, multiple myeloma (MM) ranks 24 th among the most common cancers. The Middle East and Africa are affected by an increasing trend in MM incidence, owing to several underlying factors. This systematic review aims to assess the epidemiology, patient characteristics, and treatment outcomes associated with MM in selected countries in the Middle East and Africa.

Methods

An electronic search was performed in the PubMed/MEDLINE database. Abstracts presented at the annual meetings of the American Society of Clinical Oncology, American Society of Hematology, and European Society for Medical Oncology and the GLOBOCAN registry were searched. Qualitative analysis was performed.

Results

A total of 412 articles were screened, and 14 were selected. The five-year prevalence per 100,000 gathered from country-wise GLOBOCAN data ranged between 155 in Kuwait and 5,625 in North Africa. The identified treatment options were proteasome inhibitors such as bortezomib, drugs such as thalidomide, lenalidomide, dexamethasone, melphalan, and cyclophosphamide, and newer drugs such as daratumumab.

Conclusion

Improved diagnostic capability has increased the incidence of MM in this region. However, advanced drugs and treatment regimens remain unaffordable in many countries of these regions. Therefore, understanding the trends of the disease and improving healthcare settings are imperative.

Schlagwörter

Stichwörter der Autor:innen

Middle EastMultiple myelomaepidemiologyincidencemortality

Autor:innen und Institutionen

  • Dept of Internal Medicine Hematology Unit, Cairo University, Cairo, Egypt.
  • Dept of Medicine, Hematology and Oncology American University of Beirut, Beirut, Lebanon.
  • Dept of Hematology & Stem Cell Transplant King Fahad Specialist Hospital, Dammam, Saudi Arabi.
  • Hematology Unit and Bone Marrow Transplant Center Baghdad teaching Hospital, Baghdad, Iraq.
  • Dept of Hematology Oncology Tawan Hospital, Abu Dhabi, United Arab Emirates.
  • Oncology Emerging Markets Pfizer, São Paulo, Brazil.

Zitieren

APA

Mattar, M., Bazarbachi, A., Abduljalil, O., Francis, B., Alam, A., & Blunk, V. (2024). Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review. Clinical Hematology International, 6(1). https://doi.org/10.46989/001c.92555

Vancouver

Mattar M, Bazarbachi A, Abduljalil O, Francis B, Alam A, Blunk V. Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review. Clinical Hematology International. 2024;6(1). doi:10.46989/001c.92555

BibTeX
@article{Mattar2024,
  author = {Mattar, Mervat and Bazarbachi, Ali and Abduljalil, Omar and Francis, Bassam and Alam, Arif and Blunk, Vivian},
  title = {Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review},
  journal = {Clinical Hematology International},
  year = {2024},
  volume = {6},
  number = {1},
  doi = {10.46989/001c.92555}
}
Kostenlos starten →